FIBROMYALGIA RELIEF

Manufacturer: HOMEOLAB USA INC.
Effective date: 2013-11-05
Label type: HUMAN OTC DRUG LABEL
Version: 2
Source: legacy-cache
Hydrated at: 2026-08-02 01:36:22

Label at a glance#

ProductFIBROMYALGIA RELIEF

Active ingredientCALCIUM PHOSPHATE, STRYCHNOS IGNATII SEED, CAUSTICUM, TOXICODENDRON RADICANS LEAF, MAGNESIUM PHOSPHATE, DIBASIC, BRYONIA ALBA ROOT, ARNICA MONTANA, HYPERICUM PERFORATUM, LYTTA VESICATORIA, POTASSIUM DICHROMATE

Label structure10 sections

Indications and uses

This Homeopathic product of natural source provides symptomatic relief of the pain, stiffness, fatigue and insomnia associated with fibromyalgia.

Dosage and administration

Adults: Allow 3 pellets to dissolve under the tongue three times a day or as directed by a health professional. For adult use only. Do not exceed recommended dosage.

Label contents#

Full prescribing information#

ACTIVE INGREDIENTS HPUS

OTC - ACTIVE INGREDIENT SECTION

Calcarea phosphorica 7C

Ignatia amara 9C

Causticum 7C

Rhus toxicodendron 7C

Magnesia phosphorica 7C

Bryonia alba 7C

Arnica montana 9C

Cantharis 9C

Kali bichromicum 9C

INACTIVE INGREDIENT SECTION

REFERENCES SECTION

Manufactured according to the Homeopathic Pharmacopoeia of the United States (HPUS)

PURPOSE

OTC - PURPOSE SECTION

Helps relieve pain, stiffness, fatigue and insomnia

USES

INDICATIONS & USAGE SECTION

This Homeopathic product of natural source provides symptomatic relief of the pain, stiffness, fatigue and insomnia associated with fibromyalgia.

OTC - ASK DOCTOR SECTION

If symptoms persist or worsen, discontinue use and contact a health professional.

OTC - PREGNANCY OR BREAST FEEDING SECTION

As with any drug, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep this and all medications out of reach of children.

DIRECTIONS

DOSAGE & ADMINISTRATION SECTION

Adults: Allow 3 pellets to dissolve under the tongue three times a day or as directed by a health professional.

For adult use only. Do not exceed recommended dosage.

OTHER INFORMATION

OTHER SAFETY INFORMATION

Do not use if cap seal is broken.

Homeolab USA Inc., 3025 De L'Assomption Blvd., Montreal, QC H1N 2H2 Canada

PRODUCT OF CANADA

CARTON

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

IMAGE OF CARTONIMAGE OF LABEL

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
60512-9056-1	2025-12-29	C162847	48780-1	9d75b9d0-2365-f424-e053-dadaa90a57ce	DRUG FACTS
60512-9056-1	2020-01-31	C162847	48780-1	9d75b9d0-2365-f424-e053-dadaa90a57ce	DRUG FACTS

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
60512-9056	FIBROMYALGIA RELIEF (CALCAREA PHOSPHORICA, IGNATIA AMARA, CAUSTICUM, RHUS TOXICODENDRON, MAGNESIA PHOSPHORICA, BRYONIA ALBA, ARNICA MONTANA, HYPERICUM, CANTHARIS, KALI BICHROMICUM,) PELLET [HOMEOLAB USA INC.]	2	Legacy NDC	20140508_28eb0ab3-411f-4cb3-b1ac-02002f9a308c.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
ARNICA MONTANA	ACTIVE INGREDIENT	O80TY208ZW	2
BRYONIA ALBA ROOT	ACTIVE INGREDIENT	T7J046YI2B	2
CALCIUM PHOSPHATE	ACTIVE INGREDIENT	97Z1WI3NDX	2
CAUSTICUM	ACTIVE INGREDIENT	DD5FO1WKFU	2
HYPERICUM PERFORATUM	ACTIVE INGREDIENT	XK4IUX8MNB	2
LYTTA VESICATORIA	ACTIVE INGREDIENT	3Q034RO3BT	2
MAGNESIUM PHOSPHATE, DIBASIC	ACTIVE INGREDIENT	A1Y870209Z	2
POTASSIUM DICHROMATE	ACTIVE INGREDIENT	T4423S18FM	2
STRYCHNOS IGNATII SEED	ACTIVE INGREDIENT	1NM3M2487K	2
TOXICODENDRON RADICANS LEAF	ACTIVE INGREDIENT	CDH3461U7L	2
ARNICA MONTANA	ACTIVE MOIETY	O80TY208ZW	2
BRYONIA ALBA ROOT	ACTIVE MOIETY	T7J046YI2B	2
CALCIUM CATION	ACTIVE MOIETY	2M83C4R6ZB	2
CAUSTICUM	ACTIVE MOIETY	DD5FO1WKFU	2
DICHROMATE ION	ACTIVE MOIETY	9LKY4BFN2V	2
HYPERICUM PERFORATUM	ACTIVE MOIETY	XK4IUX8MNB	2
LYTTA VESICATORIA	ACTIVE MOIETY	3Q034RO3BT	2
MAGNESIUM PHOSPHATE, DIBASIC	ACTIVE MOIETY	A1Y870209Z	2
STRYCHNOS IGNATII SEED	ACTIVE MOIETY	1NM3M2487K	2
TOXICODENDRON RADICANS LEAF	ACTIVE MOIETY	CDH3461U7L	2
LACTOSE	INACTIVE INGREDIENT	J2B2A4N98G	2
SUCROSE	INACTIVE INGREDIENT	C151H8M554	2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 16 matching rows.

FIBROMYALGIA RELIEF
CALCAREA PHOSPHORICA, IGNATIA AMARA, CAUSTICUM, RHUS TOXICODENDRON, MAGNESIA PHOSPHORICA, BRYONIA ALBA, ARNICA MONTANA, HYPERICUM, CANTHARIS, KALI BICHROMICUM,
CALCIUM PHOSPHATE
CALCIUM CATION
STRYCHNOS IGNATII SEED
CAUSTICUM
TOXICODENDRON RADICANS LEAF
MAGNESIUM PHOSPHATE, DIBASIC
BRYONIA ALBA ROOT
ARNICA MONTANA
HYPERICUM PERFORATUM
LYTTA VESICATORIA
POTASSIUM DICHROMATE
DICHROMATE ION
SUCROSE
LACTOSE

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
60512-9056	60512-9056-1

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
CALCIUM PHOSPHATE	97Z1WI3NDX	ACTIB
STRYCHNOS IGNATII SEED	1NM3M2487K	ACTIB
CAUSTICUM	DD5FO1WKFU	ACTIB
TOXICODENDRON RADICANS LEAF	CDH3461U7L	ACTIB
MAGNESIUM PHOSPHATE, DIBASIC	A1Y870209Z	ACTIM
BRYONIA ALBA ROOT	T7J046YI2B	ACTIB
ARNICA MONTANA	O80TY208ZW	ACTIB
HYPERICUM PERFORATUM	XK4IUX8MNB	ACTIB
LYTTA VESICATORIA	3Q034RO3BT	ACTIB
POTASSIUM DICHROMATE	T4423S18FM	ACTIB
SUCROSE	C151H8M554	IACT
LACTOSE	J2B2A4N98G	IACT

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 84 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
LACTOSE	LACTOSE	J2B2A4N98G	CAPSULE, COATED, EXTENDED RELEASE / ORAL	NA		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	DROPS / ORAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL		18790 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, SUGAR COATED / ORAL	NA		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, COATED / ORAL	332.05 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION / INTRAVENOUS		1950 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET / ORAL	2500 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET / SUBLINGUAL		352 mg	Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TABLET / BUCCAL	109 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION / INTRAVENOUS	203.5 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	FILM, EXTENDED RELEASE / TRANSDERMAL	675 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TROCHE / ORAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY	193.8 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET / BUCCAL	296.7 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	CAPSULE, DELAYED RELEASE / ORAL		955 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, EXTENDED RELEASE / ORAL	400 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, EMULSION / INTRAVENOUS		970 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	SYRUP / ORAL		46400 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	CAPSULE, COATED PELLETS / ORAL	135.2 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, SOLUTION / INTRAVENOUS	0.45 %w/v		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	SOLUTION / ORAL		70000 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	GRANULE, FOR SOLUTION / ORAL		42596 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, EFFERVESCENT / ORAL	96.5 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	POWDER, FOR SOLUTION / ORAL	NA		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS	9.4 %w/v		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TABLET, FILM COATED / ORAL		145 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TABLET, COATED / ORAL	516.42 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS		308 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	CAPSULE / ORAL	530 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	SUSPENSION, EXTENDED RELEASE / ORAL		5400 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS		2000 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	SUPPOSITORY / RECTAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	SUSPENSION / ORAL		48209 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS	900 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	POWDER, FOR SOLUTION / ORAL		38666 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	CAPSULE, COATED, EXTENDED RELEASE / ORAL		86 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	POWDER / RESPIRATORY (INHALATION)	90 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	GRANULE, FOR SUSPENSION / ORAL	512.5 mg/5ml		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, SOLUTION / INTRAVENOUS	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	PASTILLE / ORAL	426 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	SOLUTION / ORAL	1682 mg/15ml		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TROCHE / BUCCAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTABLE, LIPOSOMAL / INTRAVENOUS		7560 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TABLET / SUBLINGUAL	109 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION / INTRAMUSCULAR	203.5 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	GRANULE, FOR SUSPENSION / ORAL		31885 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	SOLUTION / RECTAL	8 %w/v		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	CAPSULE, COATED PELLETS / ORAL	59.8 mg		Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	TABLET, DELAYED RELEASE / ORAL		160 mg	Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	ELIXIR / ORAL		18000 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS		1 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS	133 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	CAPSULE, EXTENDED RELEASE / ORAL		619 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	LOZENGE / BUCCAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS	133 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	GRANULE / ORAL	NA		Exact identifier — unii candidate 48 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	LOZENGE / TRANSMUCOSAL		1255 mg	Exact identifier — unii candidate 48 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	OINTMENT / TOPICAL	NA		Exact identifier — unii candidate 36 equally ranked IID candidates
LACTOSE	LACTOSE	J2B2A4N98G	CAPSULE, DELAYED RELEASE / ORAL	231.84 mg		Exact identifier — unii candidate 36 equally ranked IID candidates
SUCROSE	SUCROSE	C151H8M554	TABLET, DELAYED RELEASE / ORAL	295.33 mg		Exact identifier — unii candidate 48 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
472148fa-94fd-aad6-e063-6394a90a8e5b			28eb0ab3-411f-4cb3-b1ac-02002f9a308c	2025-12-29	Warnings	Exact identifier spl set id: 28eb0ab3-411f-4cb3-b1ac-02002f9a308c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.